Laquinimod Safety Profile: Pooled Analyses from the ALLEGRO and BRAVO Trials.

Per Soelberg Sørensen,Giancarlo Comi,Timothy L Vollmer,Xavier Montalban,Ludwig Kappos,Yuval Dadon,Tali Gorfine,Maya Margalit,Nissim Sasson,Svetlana Rubinchick,Volker Knappertz

International journal of MS care（2017）

引用 13|浏览14

暂无评分

摘要

Data from these pivotal laquinimod studies demonstrate a safety profile comprising benign or manageable AEs and asymptomatic laboratory findings with a clear temporal pattern. Potential risks noted in preclinical studies were not observed.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要